Dapagliflozin trial for children with hard-to-treat brain tumors
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This Phase 1 trial tests whether dapagliflozin (an SGLT2 medicine) can help shrink or control certain pediatric brain tumors or other solid tumors that have come back or won’t respond. It’s designed mainly to check safety and early signs of effect in children and young adults who have limited treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 6 to 29 years old, and you can swallow whole pills.
- You have a recurrent brain tumor with no curative treatment left OR a solid tumor that came back/failed treatment after at least a second course of therapy.
- Your cancer can be measured by the study’s scan criteria (RANO for brain tumors or RECIST 1.1 for other solid tumors).
- You are expected to live more than 12 weeks and you can do daily activities at a “moderate” level or better (Lansky/Karnofsky score ≥ 60).
- Your blood counts and major organs (kidney, liver) meet required thresholds; oxygen levels on room air must also be adequate.
- You must not already be taking an SGLT2 inhibitor (like dapagliflozin drugs) or thiazolidinedione drugs, and you must not have type 1 diabetes or be on insulin.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial studies how safe and effective a combination of four medicines is for children and teens with certain solid tumors that have come back or cannot be controlled with standard treatment. It may help by improving tumor control, while also carefully tracking side effects.
This trial tests canagliflozin, a diabetes drug, combined with immunotherapy for people with advanced solid tumors. It may help if you have type 2 diabetes or are at risk, but you don't need diabetes to join.
This Phase 3 study tests whether metformin can improve brain function, behavior, and thinking in children and teens who were treated for certain brain tumors. You may be able to join if you meet age, time-since-treatment, language, and health/lab safety requirements.
This Phase 1/2 trial tests a study treatment for children and young adults under 22 whose brain glioma has come back or isn’t responding to prior treatment. It’s designed to see whether the treatment is safe and effective for shrinking tumors in this situation.
This trial tests a new targeted medicine (FCN-159) against standard chemotherapy for children with slow-growing brain or nervous system tumors that have a specific genetic change (BRAF alteration). The goal is to see if the new pill works better at shrinking or controlling the tumor.
This Phase 2 trial studies whether a targeted medicine that blocks MEK can work better than chemotherapy for certain slow-growing brain tumors in children. You may qualify if your tumor has specific genetic features and has not already been treated with non-surgery therapies.
Hear when a new Pediatric Brain Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.